申请人:Sumitomo Pharmaceuticals Co., Ltd.
公开号:US05719152A1
公开(公告)日:1998-02-17
A tricyclic quinoxalinedione derivative represented by the formula 1: ##STR1## wherein X represents hydrogen, alkyl, halogen, cyano, trifluoromethyl, or nitro; R.sup.1 represents hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl; G represents --CONR.sup.2 -- or --NR.sup.2 CO--, wherein R.sup.2 represents hydrogen or alkyl; J represents an acidic group or a group which is convertible thereto in vivo; E represents an basic group or a group which is convertible thereto in vivo; Y represents a single bond, alkylene, alkenylene, substituted alkylene, or Y.sup.1 --Q--Y.sup.2, wherein Y.sup.1 represents a single bond or alkylene, Y.sup.2 represents alkylene, and Q represents a heteroatom selected from oxygen or sulfur; Z represents alkylene, or a pharmaceutically acceptable salt thereof, these compounds are selective antagonists of glycine binding site of the NMDA receptor.
一种三环喹诺酮二酮衍生物,其化学式为1:##STR1## 其中X代表氢、烷基、卤素、氰基、三氟甲基或硝基;R.sup.1代表氢、烷基、环烷基或环烷基烷基;G代表--CONR.sup.2--或--NR.sup.2 CO--,其中R.sup.2代表氢或烷基;J代表酸性基团或体内可转化的基团;E代表碱性基团或体内可转化的基团;Y代表单键、烷基、烯基、取代烷基或Y.sup.1--Q--Y.sup.2,其中Y.sup.1代表单键或烷基,Y.sup.2代表烷基,Q代表从氧或硫中选择的杂原子;Z代表烷基,或其药用可接受盐,这些化合物是NMDA受体的甘氨酸结合位点的选择性拮抗剂。